GBP18.16
1.23% yesterday
London, Nov 15, 05:35 pm CET
ISIN
GB00B0LCW083
Symbol
HIK
Sector
Industry

Hikma Pharmaceuticals Stock price

GBP18.16
-1.45 7.39% 1M
-1.81 9.06% 6M
+0.97 5.64% YTD
+1.52 9.11% 1Y
-3.17 14.86% 3Y
+1.90 11.68% 5Y
+3.05 20.20% 10Y
London, Closing price Fri, Nov 15 2024
+0.22 1.23%
ISIN
GB00B0LCW083
Symbol
HIK
Sector
Industry

Key metrics

Market capitalization GBP4.03b
Enterprise Value GBP4.84b
P/E (TTM) P/E ratio 17.82
EV/FCF (TTM) EV/FCF 17.12
EV/Sales (TTM) EV/Sales 2.02
P/S ratio (TTM) P/S ratio 1.68
P/B ratio (TTM) P/B ratio 2.23
Dividend yield 3.46%
Last dividend (FY23) GBP0.62
Revenue growth (TTM) Revenue growth 5.67%
Revenue (TTM) Revenue GBP2.40b
EBIT (operating result TTM) EBIT GBP393.10m
Free Cash Flow (TTM) Free Cash Flow GBP282.90m
EPS (TTM) EPS GBP1.02
P/E forward 11.75
P/S forward 1.69
EV/Sales forward 2.03
Show more

Is Hikma Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Hikma Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Hikma Pharmaceuticals forecast:

6x Buy
55%
5x Hold
45%

Analyst Opinions

11 Analysts have issued a Hikma Pharmaceuticals forecast:

Buy
55%
Hold
45%

Financial data from Hikma Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
2,396 2,396
6% 6%
100%
- Direct Costs 1,333 1,333
11% 11%
56%
1,063 1,063
0% 0%
44%
- Selling and Administrative Expenses 402 402
38% 38%
17%
- Research and Development Expense 116 116
0% 0%
5%
545 545
17% 17%
23%
- Depreciation and Amortization 152 152
5% 5%
6%
EBIT (Operating Income) EBIT 393 393
21% 21%
16%
Net Profit 226 226
90% 90%
9%

In millions GBP.

Don't miss a Thing! We will send you all news about Hikma Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Riad Mishlawi
Employees 9,100
Founded 1978
Website www.hikma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today